SETD2 Mutations in Prognosis and Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia |
Dana-Farber Cancer Institute / Brenton Mar, MD, PhD |
Young Investigator Grants |
2014 |
Massachusetts |
Targeting MYC/MYCN-driven Transcriptional Amplification in Pediatric Cancer |
Dana-Farber Cancer Institute / Rani George, M.D., Ph.D. |
Innovation Grants |
2014 |
Massachusetts |
Mechanisms of CNOT3 Tumor Suppression in T-ALL and Identification of New Drugs That Specifically Kill CNOT3-Deficient T-ALL Cells |
Dana-Farber Cancer Institute / Zhaodong Li, PhD |
Young Investigator Grants |
2014 |
Massachusetts |
Therapies for SHH-subtype Medulloblastoma |
Dana-Farber Cancer Institute / Rosalind Segal, M.D., Ph.D. |
Innovation Grants |
2014 |
Massachusetts |
Mechanisms and Targeted Inhibition of NT5C2 Mutations in Relapsed ALL |
Columbia University / Adolfo A. Ferrando, M.D., Ph.D. |
Innovation Grants |
2014 |
New York |
Neurocognitive Assessments within COG: An Intensive, Integrated Model for Successfully Evaluating Children with High-Risk ALL |
Children’s Research Institute / Kristina Hardy, PhD |
Psychosocial Grants |
2014 |
District of Columbia |
Exosomes as Biomarkers to Monitor Disease Progression and Response to Therapy in Ewing sarcoma |
Children’s Mercy / Glenson Samuel, MD |
Young Investigator Grants |
2014 |
Missouri |
Two-pronged Cell Therapy: Engineering T Cells to Redirect Bystander T- and NK-Cells to Pediatric Cancer |
Baylor College of Medicine / Stephen Gottschalk, M.D. |
Innovation Grants |
2014 |
Texas |
STAT3 Signaling Profiles Predict Response to Chemotherapy in Pediatric AML |
Baylor College of Medicine / Michele Redell, M.D./Ph.D. |
Springboard Grants |
2014 |
Texas |
Optimizing Engager T-cells for CD19+ Malignancies |
Baylor College of Medicine / Mireya Paulina Velasquez, MD |
Young Investigator Grants |
2014 |
Texas |